지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 1,031 - 1,034 (4page)
이용수
초록· 키워드
오류제보하기
High-dose methotrexate-based chemotherapy has extended survival in patients with primary central nervous system lymphoma (PCNSL). However, although salvage treatment is necessary in recurrent and refractory PCNSL, this has not been standardized. We herein describe the efficacy of a combination of rituximab and temozolomide (TMZ) in two consecutive patients with recurrent and refractory PCNSL. Based on the immunohistochemical study, case 1 had a non-germinal center B-cell-like (non-GCB) subtype, was positive for bcl-2 and negative for O6-methylguanine-DNA methyltransferase (MGMT). Case 2 was GCB subtype, bcl-2-, and MGMT+. Because of the positive expression of MGMT, interferon-beta was additionally given in case 2. Complete responses and partial responses were obtained after the third and fourth cycles of combination therapy, respectively. This was maintained for 12 months, with acceptable toxicity. The combination of rituximab and TMZ was effective in tumors with different immunohistochemical profiles. This combination therapy warrants further study in a larger population.
목차
등록된 정보가 없습니다.
참고문헌 (17)
참고문헌 신청
Braaten KM / 2003 / BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma / Clin Cancer Res 9 : 1063 ~ 1069
Camilleri-Broet S / 2006 / A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
Coiffier B / 2002 / CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma / N Engl J Med 346 : 235 ~ 242
Enting RH / 2004 / Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide / Neurology 63 : 901 ~ 903
Fu K / 2008 / Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of di
Camilleri-Broet S / 2006 / A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
Coiffier B / 2002 / CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma / N Engl J Med 346 : 235 ~ 242
Enting RH / 2004 / Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide / Neurology 63 : 901 ~ 903
Fu K / 2008 / Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of di
이 논문의 저자 정보
최근 본 자료
댓글(0)
0